0001654954-19-010400.txt : 20190905 0001654954-19-010400.hdr.sgml : 20190905 20190905160038 ACCESSION NUMBER: 0001654954-19-010400 CONFORMED SUBMISSION TYPE: RW PUBLIC DOCUMENT COUNT: 1 FILED AS OF DATE: 20190905 DATE AS OF CHANGE: 20190905 FILER: COMPANY DATA: COMPANY CONFORMED NAME: TG THERAPEUTICS, INC. CENTRAL INDEX KEY: 0001001316 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 363898269 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: RW SEC ACT: SEC FILE NUMBER: 333-233565 FILM NUMBER: 191077197 BUSINESS ADDRESS: STREET 1: 2 GANSEVOORT STREET, 9TH FLOOR CITY: NEW YORK STATE: NY ZIP: 10014 BUSINESS PHONE: (212) 554-4484 MAIL ADDRESS: STREET 1: 2 GANSEVOORT STREET, 9TH FLOOR CITY: NEW YORK STATE: NY ZIP: 10014 FORMER COMPANY: FORMER CONFORMED NAME: MANHATTAN PHARMACEUTICALS INC DATE OF NAME CHANGE: 20030310 FORMER COMPANY: FORMER CONFORMED NAME: ATLANTIC TECHNOLOGY VENTURES INC DATE OF NAME CHANGE: 20000330 FORMER COMPANY: FORMER CONFORMED NAME: ATLANTIC PHARMACEUTICALS INC DATE OF NAME CHANGE: 19960703 RW 1 tgtx_formrw.htm FORM RW Blueprint
 
  TG THERAPEUTICS, INC.
52 Gansevoort Street, 9th Floor
New York, New York 10014
 
September 5, 2019
 
VIA EDGAR
 
U.S. Securities and Exchange Commission
 
Division of Corporation Finance
 
100 F Street, N.E.
 
Washington, D.C. 20549
 
Re:         
TG Therapeutics, Inc. (CIK 0001001316)
 
Application for Withdrawal of Registration Statement on Form S-3 filed on
 
August 30, 2019 (File No. 333-233565)
 
Ladies and Gentlemen:
 
Pursuant to Rule 477 promulgated under the Securities Act of 1933, as amended, (the “Securities Act”), TG Therapeutics, Inc., a Delaware corporation (the “Company”), hereby requests the immediate withdrawal of the Company's registration statement on Form S-3, which was initially filed with the Securities and Exchange Commission (the “Commission”) on August 30, 2019 under File Number 333-233565 (together with all exhibits thereto, the “Registration Statement”). The Registration Statement has not been declared effective by the Commission, and no securities have been issued or sold under the Registration Statement.
 
The Company intended to file the Registration Statement under submission type “S-3ASR” as an automatic shelf registration statement of securities of a well-known seasoned issuer, but due to an incorrect coding of the EDGAR submission header, the Registration Statement was treated as a submission type “S-3” rather than an immediately-effective “S-3ASR” submission. The Company is therefore requesting that the Registration Statement be immediately withdrawn.
 
Following the withdrawal, the Company plans to file a replacement Registration Statement under submission type “S-3ASR.”
 
Should you have any questions regarding the foregoing application for withdrawal, please contact Mark McElreath, our legal counsel in connection with the Registration Statement, at (212) 210-9595 or mark.mcelreath@alston.com.
 
 
 
Very truly yours,
 
 
TG Therapeutics, Inc.
 
 
 
 
 

By:  
/s/ Sean A. Power
 
 
 
Sean A. Power
 
 
 
Chief Financial Officer
 
 
 
Principal Financial and Accounting Officer